表紙
市場調查報告書

中國的Rituximab市場分析

Investigation Report on Chinese Rituximab Market, 2018-2022

出版商 China Research and Intelligence 商品編碼 296864
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Rituximab市場分析 Investigation Report on Chinese Rituximab Market, 2018-2022
出版日期: 2018年07月17日內容資訊: 英文 30 Pages
簡介

Rituximab(Roche公司「MabThera」、Genentech公司「Rituxan」)是1997年已核准的腫瘤治療藥──對CD20抗原的嵌合單株抗體。在治療B細胞淋巴瘤上非常有效,展現出良好的抗性。全球Rituximab市場銷售額在2011年為61億4,000萬美元,2012年為71億4,300萬美元,之後順利成長,到2014年超過80億美金的規模。

本報告提供中國的Rituximab市場相關調查分析、提供主要廠商的市場佔有率、醫院市場上的銷售價格、醫院市場上的市場佔有率(各劑型)、自體免疫疾病的發病率、學名藥的製造計劃、市場預測等資訊,為您概述為以下內容。

第1章 Rituximab的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Rituximab的市場概要

  • 專利狀況
  • 主要製造商
  • 市場規模

第3章 中國的Rituximab的銷售額分析

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的Rituximab的主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售量

第5章 中國的Rituximab(各劑型)的市場規模分析

  • 市場佔有率:各銷售額、劑型
  • 市場佔有率:各銷售量、劑型

第6章 中國的醫院市場上Rituximab的標準價格

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第7章 中國的Rituximab的主要製造商

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第8章 中國的Rituximab市場預測

  • 非何杰金氏淋巴瘤、自體免疫疾病的發病率的預測
  • Rituximab市場規模的預測
  • Rituximab競爭格局的預測

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1807311

Description

Rituximab (Roche's trade name: Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc.

The global sales of Rituximab have been very mature. In fiscal year 2017, Rituximab recorded a revenue of CHF 7.388 billion, a YOY increase of 1.21%. The drug was mostly used for tumor treatment. In fiscal year 2017, the sales value from tumor treatment reached CHF 5.832 billion, increasing by 0.15% YOY, and the sales value from the treatment of autoimmune diseases reached CHF 1.556 billion, increasing by 5.35% YOY. In China, Roche's Rituximab is mainly used to treat non-Hodgkin lymphoma.

As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin's disease in China. The incidence of non-Hodgkin's lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 70 cases per 1 million people today. Autoimmune diseases may affect organs such as the central nervous system, lungs, liver and kidneys, cause dysfunction or even failure of organs, and ultimately threaten life. Statistics show that there are about 30 to 40 million people suffering from autoimmune diseases in China, which leads to a growing demand for Rituximab. In 2017, the sales value of Rituximab exceeded CNY 1 billion in China.

According to CRI, by Jul. 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech. Several domestic manufacturers have applied for approval to produce generic Rituximab. It is expected that generic Rituximab will be launched after 2020. There is still a large growth potential for the Chinese Rituximab market.

Topics Covered:

  • Development environment of Chinese Rituximab market
  • Sales of Rituximab in China
  • Prices of Rituximab in China
  • Progress of generic Rituximab in China
  • Prospects of Chinese Rituximab Market, 2018-2022

Table of Contents

Table of Contents

1 Basic Concepts of Rituximab

  • 1.1 Indications for Rituximab
  • 1.2 Development History of Rituximab in China
  • 1.3 Governmental Approval of Rituximab in China

2 Sales of Rituximab in China, 2013-2017

  • 2.1 Sales Value of Rituximab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value in Parts of China
  • 2.2 Sales Volume of Rituximab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume in Parts of China
  • 2.3 Sales of Rituximab by Dosage Form

3 Major Rituximab Manufacturers in China, 2013-2017

  • 3.1 Market Share of Major Rituximab Manufacturers in China
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Roche
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Roche's Rituximab in China
  • 3.3 Genentech
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Genentech's Rituximab in China

4 Prices of Rituximab in China, 2017-2018

  • 4.1 Average Prices of Rituximab in China
    • 4.1.1 National Average Price
    • 4.1.2 Average Price by Region
  • 4.2 Prices of Major Manufacturers' Rituximab in China
    • 4.2.1 Price of Roche's Rituximab in China
    • 4.2.2 Price of Genentech's Rituximab in China

5 Prospects of Chinese Valsartan Market, 2018-2022

  • 5.1 Factors Influencing Rituximab Development in China
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Competition Pattern

Selected Charts

  • Chart Rituximab Products Approved to Market in China by 2018
  • Chart Sales Value of Rituximab in China, 2013-2017
  • Chart Sales Value of Rituximab by Region in China, 2013-2017
  • Chart Market Share of Rituximab Manufacturers by Sales Value in China, 2013-2017
  • Chart Prices of Roche's Rituximab in Key Regions of China, 2017-2018
  • Chart Prices of Genentech's Rituximab in Key Regions of China, 2017-2018
  • Chart Forecast on Sales of Rituximab in China, 2018-2022
  • Chart Generic Rituximab in China
Back to Top